^
    over2years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=19, Terminated, WindMIL Therapeutics | Trial completion date: Mar 2027 --> Nov 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Oct 2021; Resourcing
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over3years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=19, Active, not recruiting, WindMIL Therapeutics | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over3years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=23, Recruiting, WindMIL Therapeutics | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Mar 2022 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes
    over4years
    [VIRTUAL] Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC). (ASCO 2020)
    Patients will undergo lymphodepletion (fludarabine 300 mg/m2/day and cyclophosphamide 30 mg/m2/day on days -5,-4,-3) followed by infusion of MILs on day 0...The first patient was treated in December 2019. Research Funding: None
    P2a data • Combination therapy
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • fludarabine IV • cyclophosphamide intravenous • marrow infiltrating lymphocytes
    almost5years
    Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=23, Recruiting, WindMIL Therapeutics | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jul 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
    |
    Opdivo (nivolumab) • marrow infiltrating lymphocytes